31 January 2007 - Naturex generated full-year 2006 revenue of EUR 66.2 million, up 31.9% on 2005, continuing its strong growth despite an unfavorable trend in the dollar exchange rate over the second half of the year.
| In EUR millions |
2005* |
2006 |
Change at
current USD
rates (%) |
Change at
constant USD
rates |
| Q1 |
8.3 |
18.3 |
+119.6% |
+102.2% |
| Q2 |
10.4 |
16.4 |
+57.8% |
+56.1% |
| Q3 |
15.7 |
15.0 |
-4.4% |
-1.2% |
| Q4 |
15.8 |
16.5 |
+4.7% |
+10.7% |
| Total 12 months |
50.2 |
66.2 |
+31.9% |
+31.6% |
| USD rate |
1,250 |
1,249 |
|
|
*Pure World consolidated as of July 1, 2005
Neutraceuticals represent 61.3% of revenue, flavoring and food processing 31.6% and cosmetics 3.9%. The United States and Canada accounted for 68.6% of the Group’s revenue, while Europe generated 27.4% and Asia/Pacific 3.1%.
Continued strong organic growth
| In EUR millions |
31/12/2005* |
31/12/2006 |
Change |
| Total revenue |
63.4 |
66.2 |
+4.4% |
| Pure World business line closure underway |
6.0 |
1.9 |
-68.3% |
| Toll extraction (Europe) |
0.9 |
0.3 |
-66.7% |
| Proprietary activity |
56.5 |
64.0 |
+13.3% |
*Pure World integrated over 12 months in 2005
Excluding the impact from the planned gradual closure of non-strategic business lines (Pure World business line closure underway and toll extraction in Europe), pro forma growth stood at 13.3% (up 13.0% at constant USD).
Creation of a subsidiary in the United Kingdom
Furthermore, as planned, Naturex has just created a subsidiary in Oxford in the United Kingdom which will enable the Group to reinforce its proximity and links with UK clients, while also leading to an accelaration in organic growth on this major market which is one of the most buoyant in Europe.
Recent broadening of scope
Lastly, following the acquisition announced on January 23 of Italian company, Hammer Pharma, specialized in pharmaceuticals and neutraceuticals, Naturex has broadened its proforma scope to EUR 74 million and intends to maintain a sustained rate of growth in 2007.